Becton, Dickinson and Company (NYSE:BDX) Position Increased by Hyman Charles D

Hyman Charles D grew its position in Becton, Dickinson and Company (NYSE:BDX) by 5.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,554 shares of the medical instruments supplier’s stock after buying an additional 134 shares during the quarter. Hyman Charles D’s holdings in Becton, Dickinson and Company were worth $623,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Verdence Capital Advisors LLC boosted its stake in Becton, Dickinson and Company by 5.7% in the 3rd quarter. Verdence Capital Advisors LLC now owns 1,411 shares of the medical instruments supplier’s stock worth $365,000 after purchasing an additional 76 shares during the period. IFM Investors Pty Ltd boosted its stake in Becton, Dickinson and Company by 3.5% in the 3rd quarter. IFM Investors Pty Ltd now owns 55,888 shares of the medical instruments supplier’s stock worth $14,449,000 after purchasing an additional 1,890 shares during the period. Foyston Gordon & Payne Inc boosted its stake in Becton, Dickinson and Company by 4.5% in the 3rd quarter. Foyston Gordon & Payne Inc now owns 38,783 shares of the medical instruments supplier’s stock worth $10,027,000 after purchasing an additional 1,664 shares during the period. Value Partners Investments Inc. boosted its stake in Becton, Dickinson and Company by 5.2% in the 3rd quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock worth $225,000 after purchasing an additional 43 shares during the period. Finally, NBT Bank N A NY boosted its stake in Becton, Dickinson and Company by 73.5% in the 3rd quarter. NBT Bank N A NY now owns 2,949 shares of the medical instruments supplier’s stock worth $762,000 after purchasing an additional 1,249 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

Separately, Barclays lifted their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $281.40.

Insider Activity

In other news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is owned by insiders.

Becton, Dickinson and Company Stock Up 0.2 %

Shares of NYSE:BDX traded up $0.56 during trading on Tuesday, reaching $237.14. 1,120,070 shares of the company traded hands, compared to its average volume of 1,408,706. The firm has a fifty day simple moving average of $238.27 and a 200 day simple moving average of $239.97. The firm has a market cap of $68.54 billion, a P/E ratio of 52.23, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. Becton, Dickinson and Company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.86 EPS. Analysts anticipate that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be issued a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.60%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.